<DOC>
	<DOC>NCT01851850</DOC>
	<brief_summary>The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.</brief_summary>
	<brief_title>Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>clinical diagnosis with PD subjects who are willing to participate in the trial. subjects who participated in the BIA 91067302 clinical trial. subjects who didn't take part at the BIA 91067302 clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>PD</keyword>
	<keyword>Off periods</keyword>
	<keyword>quality of life</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>end-off-dose motor fluctuations</keyword>
</DOC>